The Cryo-EM Market in 2026

Cryo electron microscopy went from a niche technique to a mainstream structural-biology workhorse in under a decade, and the money followed. The global cryo-EM market was worth about $1.40 billion in 2024 and roughly $1.56 billion in 2025, with independent forecasters projecting it to pass $2.7 billion by 2030 Research and Markets, 2024. Analyst CAGR estimates cluster between 10.5% and roughly 15% through the early 2030s, depending on how each firm scopes instruments, detectors, software and services Data Bridge Market Research, 2025.

For a founder, the headline number matters less than where the growth sits. Two facts should shape your plan. First, single-particle analysis held about 47% of the market in 2024, and structural biology applications held roughly 42% in 2025 — this is a market driven by drug discovery, not by materials science curiosity SNS Insider, 2025. Second, the services segment is the fastest-growing part of the market, because the instruments are so expensive that most labs would rather rent capability than own it Coherent Market Insights, 2025. That second fact is your business.

A cryo electron microscopy business is not a lab that publishes papers. It is a fee-for-service operation that sells sample preparation, screening, data collection and structure determination to pharmaceutical companies, biotech startups and academic groups that cannot justify buying a $6 million microscope or hiring the specialists to run it. The high upfront capital cost and operational complexity of cryo-EM systems is precisely what created a robust market for contract research organisations (CROs) and shared facilities charging on a fee-for-service basis. Your plan sells access, speed and expertise.

Demand comes from a specific customer: the drug-discovery scientist who needs to see how a candidate molecule binds a target protein. Cryo-EM captures proteins in a near-native, frozen-hydrated state without the crystals that X-ray methods require, which makes it the technique of choice for membrane proteins, large complexes and antibody-antigen interactions. When a biotech maps a GLP-1 receptor bound to a small-molecule agonist, or a startup needs the structure of a novel PROTAC complex, cryo-EM is often the only route. A business plan that names these use cases reads as written by someone who understands the buyer. A plan that talks about "the growing healthcare industry" does not.

One nuance worth putting in your plan: the market splits between capital-rich buyers who eventually build their own facilities and everyone else who outsources indefinitely. Your addressable market is the second group — small and mid-cap biotechs, academic labs without a local Krios, and even large pharma teams that outsource overflow work to protect their internal instrument schedule. Sizing that segment credibly, rather than quoting the whole $1.56 billion market, is what separates a fundable plan from a hopeful one.

Who actually buys cryo-EM services

A credible plan names three distinct customer groups and shows how the offer, pricing and turnaround shift for each. The first is venture-backed biotech, typically small teams working on a specific target who need a structure fast to inform the next round of medicinal chemistry and often to support their own fundraising milestones. They are price-tolerant and speed-sensitive, and they generate repeat work as programmes iterate. The second is large pharma discovery teams, who usually own instruments but outsource overflow, unusual sample classes, or work they want kept off the internal schedule; these accounts are harder to win but larger and stickier once earned. The third is academic and translational labs without local high-end instruments, who value access and hands-on expertise and can anchor early revenue while the industry book builds.

The buying trigger differs by group, and your marketing plan should say so. Biotech buys when a lead candidate needs a structure to advance or to satisfy an investor question. Pharma buys when internal capacity is full or a sample is awkward. Academic groups buy when a grant funds a specific structural aim. Mapping each trigger to a channel — warm referral, conference relationship, or technical content — turns a generic "we will do outreach" plan into one a reviewer can believe.

Quick Answers Before You Plan

These are the questions prospective founders search for most. Short answers here; the detail sits in the sections below.

The pattern across these answers is consistent: cryo-EM rewards founders who match their capital commitment to proven demand. Almost every failure in this niche traces back to buying an instrument before the order book justified it. Keep that principle in view as you read the cost and revenue sections.

Startup Costs & Capital Requirements

There is no single startup number for a cryo-EM business, because two founders can pursue the same market with capital budgets that differ by a factor of fifty. The right figure for your plan depends entirely on whether you own the instrument or rent it. Both models are legitimate, and the strongest plans often stage from one to the other.

The instruments set the ceiling

The microscope dominates the capital question. A 300 kV Thermo Fisher Titan Krios — the flagship for high-resolution single-particle work — costs more than $6 million, and at roughly four metres tall it needs a purpose-built room Science, AAAS. A 200 kV Glacios sells for about half that, near $3 million, and a 100 kV Tundra screening instrument runs around $1 million C&EN, 2020. Screening-class scopes such as the Talos Arctica generally land 30–50% below Krios pricing CryoEM Services, 2026. These are list-level figures; real quotes move with detector choice, energy filters and install.

Three cost profiles

Map your plan to one of three builds. An asset-light service — sample-prep lab, staff and outsourced microscope time — needs roughly $150,000 to $600,000. An in-house screening facility owning a Glacios or Tundra typically needs $2 million to $4.5 million once you add a detector, room and install. A full 300 kV Krios facility lands at $8 million to $12 million or more. Investors will judge whether the model you chose matches the demand you can prove.

Cost breakdown (in-house screening build)

• Screening or entry microscope (Glacios / Tundra): $1M–$3M
• Direct electron detector (Gatan K3 or Falcon 4): $300K–$1.2M
• Purpose-built room — vibration isolation, EM shielding, HVAC: $250K–$1M fit-out
• Sample-prep suite (Vitrobot, plasma cleaner, cryo-storage, LN2/ethane): $120K–$300K
• Compute + storage for RELION / cryoSPARC processing: $60K–$250K
• Annual microscope service contract: $120K–$300K per year

The line most first-time founders underestimate is the room. Vibration, electromagnetic interference and temperature drift will cap your achievable resolution regardless of how good the microscope is, and remediating a bad room after install is far more expensive than building it right. Treat the room as part of the instrument, not as generic office fit-out.

Funding routes for a capital-heavy service

Because the core asset is a multi-million-dollar instrument with a long useful life, cryo-EM is a strong fit for SBA 504 financing in the US, which is designed for major equipment and real property with extended amortisation and a relatively low down payment. Working capital and softer costs suit an SBA 7(a) loan. Founders with a research angle — new sample-prep methods, automation, AI-assisted processing — should pursue SBIR and STTR grants from the NIH and NSF, which fund service-linked innovation without diluting equity. In the UK, the common stack is Innovate UK grants, the Biomedical Catalyst, generous R&D tax credits, and SEIS/EIS equity for early rounds. Our bespoke business plan service builds lender-ready and grant-ready versions of the same financial model.

One structuring tip that repeatedly helps at the funding stage: separate the instrument financing from the operating company. Many facilities hold the microscope in an equipment-owning entity financed through SBA 504 or a lease, then have the operating company pay for usage. It keeps the operating P&L legible to investors and isolates the largest liability. Whichever structure you choose, the plan should show the debt service against a conservative utilisation ramp, because a lender's first question is always whether the scope can cover its own payment.

Where Cryo-EM Facilities Cluster

Location is a commercial decision, not just a real-estate one. Cryo-EM demand concentrates around biotech capital and academic anchors, and proximity to clients shortens both the sales cycle and the sample-shipping risk. A plan that names its catchment reads as researched; one that says "we will serve customers nationally" does not.

• Cambridge / Boston, Massachusetts: the densest US biotech cluster and a natural home for a service facility; NanoImaging Services opened an East Coast lab here to sit near clients.
• San Diego, California: a second US anchor; NanoImaging Services runs a West Coast facility serving the region's antibody and small-molecule programmes.
• San Francisco Bay Area: deep academic cryo-EM (UCSF, Berkeley, Stanford's CEMC) and a heavy concentration of venture-backed biotech buyers.
• Oxford–Cambridge–Didcot, UK: anchored by Diamond Light Source's eBIC national facility; strong for founders selling into UK and EU pharma.
• Strasbourg, France & the Munich region, Germany: home to NovAliX and Proteros respectively, showing that EU demand supports commercial cryo-EM outside the UK.

Two practical location factors deserve a line in the plan. First, floor stability: high-resolution scopes prefer a ground-floor or basement slab away from lifts, HVAC plant and road vibration, which quietly narrows your building shortlist. Second, logistics: samples ship frozen on dry ice or under strict cold-chain, so being within a short courier window of your core clients materially reduces failed shipments. Founders who plan to serve a national market anyway should budget for robust inbound cold-chain handling rather than assuming clients will absorb that risk.

Revenue, Rates & Unit Economics

Cryo-EM pricing has two layers: hourly instrument time and packaged projects. Academic cores publish the clearest benchmarks. They typically charge $100–$200 per hour for internal users and $250–$500 per hour for external users, with single-sample screening around $260 internal, $430 external and $500 for industry clients CryoEM Services, 2026. Commercial CROs price above these levels because they sell speed and confidentiality rather than subsidised academic access.

At the project level, a full single-particle job — sample prep, screening, data collection and processing — runs about $5,000 to $25,000 at an academic facility and $15,000 to $80,000 at a private CRO NanoImaging Services. The wide range reflects difficulty: a well-behaved soluble protein resolves quickly, while a fragile membrane-protein complex can consume weeks of optimisation. Your pricing model should tier by sample class, not offer a single flat rate.

Turnaround is the lever industry clients pay for. Academic cores usually deliver in two to three weeks once a sample arrives, but queues can stretch the real wait to four to twelve weeks. CROs turn projects in one to two weeks, and NanoImaging Services markets an under-four-week sample-to-structure workflow. When you position against a university core, you are not competing on price — you are selling the removed queue, the dedicated operator and the confidentiality a shared academic instrument cannot promise.

The number that actually drives the business: utilisation

Most guides stop at headline rates. The figure that decides whether a cryo-EM facility survives is billable microscope-days per year. A screening scope billing an industry day-rate of $1,500–$2,500, or a Krios session at $2,000–$4,000 per day, only pays for itself if it runs a high share of the ~250 working days in a year. A scope at 25% utilisation is a liability that still owes a service contract, cryogens and operator salaries; the same scope at 60% is a strong asset. Your financial model should forecast the utilisation ramp month by month, because that curve — not the day-rate — is what a lender or investor stress-tests first.

Worked example — a Glacios-first facility, year 2

Consider a facility that buys a Glacios in year two after an asset-light year one. It charges an $1,800 industry day-rate for screening and $6,000–$18,000 per single-particle project. Assume it delivers 180 billable microscope-days and completes 24 projects at a blended $11,000. Screening and day-rate work contributes roughly $324,000; project work contributes about $264,000; add sample-prep-only and consulting income and the top line models to roughly $1.1M–$1.4M. Against that, a $200,000 service contract, cryogens, two operators and compute leave the business EBITDA-negative in year one and moving to an 18–28% margin as utilisation climbs through year two into year three. Those are planning figures for your model to localise, not a guarantee — but they show why the ramp, not the rate card, is the story.

Recurring revenue is the quiet multiplier. A biotech that runs one successful project rarely runs only one; medicinal-chemistry programmes iterate, generating a steady stream of related complexes. A plan that models repeat rate and account expansion — not just new logos — will forecast far more realistic year-three revenue than one that assumes every project is a fresh sale.

Three Ways to Enter the Market

The single most important strategic choice in this business is how much capital to commit before you have proven demand. These three models sit on that spectrum. Your plan should name which one you are building and why it fits your evidence of demand and access to capital.

A common and defensible path stages across these rows: launch asset-light, win two or three repeat industry accounts, then finance a screening scope on the back of that book, and only reach for a Krios once contracted demand covers the debt service. Sequencing the models this way is easier to fund than asking a lender to underwrite an idle $6 million instrument on a promise.

Common mistakes that sink cryo-EM startups

• Buying a Krios before demand is committed. A $6M scope at 20% utilisation bankrupts the model no matter how good the science is.
• Treating the room as an afterthought. Vibration, EM shielding and HVAC can cost as much as the prep suite and cannot be retrofitted cheaply.
• Under-pricing sample prep. Grid-making and vitrification is where most projects fail; it deserves its own priced line, not a giveaway.
• Applying academic rates to industry clients. Pharma buyers pay a premium for speed and confidentiality — pricing at core-facility rates leaves money on the table.
• Skipping the quality system. Without GMP or GLP capability you are locked out of the regulatory-grade work that carries the best margins.

How a Cryo-EM Project Runs

Investors and clients both want to see that you understand the work, not just the market. The operations section of your plan should walk through the sample-to-structure pipeline, because every stage carries a cost, a failure mode and a place where a good service provider earns its premium. Describing this pipeline in plain terms is one of the clearest ways to signal that the founding team has actually done the job.

Stage one — sample intake and quality control

A project starts before any electrons are fired. The client ships purified protein or a complex, usually frozen on dry ice under cold-chain, and the facility runs incoming quality control: concentration, purity, and behaviour by size-exclusion chromatography or a quick negative-stain check. A surprising share of projects stall here because the sample is not homogeneous enough to image well. Building intake QC into your workflow — and pricing it as a distinct step — protects both your instrument time and the client relationship, because it catches problems before they consume expensive Krios sessions.

Stage two — grid preparation and vitrification

This is the craft that separates a good facility from a mediocre one. The sample is applied to a grid, blotted and plunge-frozen in liquid ethane on a device such as a Vitrobot, trapping molecules in a thin layer of vitreous ice. Ice thickness, particle distribution and preferred orientation are decided here, and they determine whether the downstream data is usable. Because this step is skill-intensive and iterative, it is where projects most often fail and where an experienced operator adds the most value. Any credible plan treats grid optimisation as a priced service, not a throw-in.

Stage three — screening and data collection

Grids are first screened on a lower-voltage instrument — a Glacios, Talos Arctica or Tundra — to confirm ice quality and particle behaviour before committing high-value time. Promising grids then move to a 300 kV Krios for automated data collection, typically run overnight and across days using software such as EPU with a direct electron detector like a Gatan K3 or Falcon 4. A single session can generate thousands of movies and terabytes of data, which is why compute and storage are a real line item, not an afterthought.

Stage four — processing and structure determination

Raw movies are motion-corrected, particles are picked and classified, and a 3D reconstruction is refined using RELION or cryoSPARC on a GPU cluster. The output is a density map and, often, an atomic model the client can use for structure-based drug design. Turnaround here depends on both compute and human expertise, and it is the stage where automation and in-house method development can widen your margin. Facilities that invest in efficient processing pipelines can quote the shorter turnarounds that industry clients pay a premium for.

Laying out these four stages in your plan does two things at once. It reassures technical diligence that you can actually deliver, and it justifies your pricing tiers, because each stage is a genuine unit of work with its own cost and failure rate. A plan that prices the whole thing as one flat "structure fee" hides exactly the operational detail that builds confidence.

Winning Your First Clients

Cryo-EM is a referral-driven, reputation-heavy market, which is good news for a credible founder and hard for an anonymous one. Buyers are structural biologists and discovery scientists who trust demonstrated competence far more than advertising. Your go-to-market plan should reflect how these customers actually choose a provider, and it should be honest that the first handful of accounts are won on relationships and proof, not on a marketing funnel.

Lead with proof, not promotion

The single strongest asset a new facility has is the founding team's track record — datasets solved, structures deposited, and named collaborators. A plan should put that credibility front and centre and channel it into concrete proof: a small number of well-documented case structures, ideally spanning a soluble protein, a membrane protein and a protein-ligand complex, so a prospect can see you handle their sample class. This is the technical equivalent of a portfolio, and it converts far better than any claim about turnaround.

Go where the buyers already are

Structural-biology and drug-discovery conferences, cryo-EM user meetings, and the technical sessions at events run by the field's instrument makers are where accounts start. Warm introductions from former academic colleagues now working in industry are the highest-yield channel of all. A plan that budgets for conference presence and technical seminars — and names the specific events — reads as far more realistic than one that assumes inbound leads from search traffic in a market this specialised.

Publish the work that demonstrates capability

Application notes, method write-ups and short technical pieces on solving difficult sample classes do double duty: they help clients and they prove competence to the next prospect. Providers such as NanoImaging Services, Shuimu Biosciences and Creative Biostructure all lead with technical content rather than salesy copy, because their buyers read it. Your marketing plan should commit to a modest, sustainable cadence of genuinely useful technical content rather than generic promotion.

Design for the repeat, not the one-off

The economics of this business live in repeat work. A discovery programme that solves one structure usually needs the next analogue, the next complex, the next optimisation cycle. Winning the first project is expensive; keeping the account is where the margin compounds. A go-to-market plan should therefore invest as heavily in delivery quality, communication and turnaround reliability as in acquisition, because a delighted first client becomes both a repeat buyer and a reference for the next one.

Compliance, Accreditation & Safety

Cryo-EM has no single operating licence, but the compliance you carry decides which clients you can serve. Research-grade data sells to discovery teams; regulatory-grade data sells to development teams, and the latter pays more. The difference is a quality system.

United States

• cGMP / GLP quality system (21 CFR): required to sell cryo-EM data into biologics and regulatory submissions. NanoImaging Services operates the first cGMP-compliant cryo-TEM lab in North America — a signal of how much this capability is worth to pharma clients.
• OSHA cryogen and high-voltage safety: liquid nitrogen and liquid ethane handling, oxygen-deficiency monitoring, and 300 kV high-voltage safety are core to daily operation.
• State business and lab registration: plus institutional biosafety review (IBC) and appropriate BSL controls if you image infectious agents.

United Kingdom

• UKAS ISO/IEC 17025 accreditation: the recognised signal of analytical competence for accredited testing work, valued by pharma buyers.
• MHRA GMP: needed to support UK and EU biologics submissions with regulatory-grade characterisation data.
• HSE cryogen and pressure-systems compliance: COSHH assessments for cryogens plus pressure-systems safety. The UK's reference point is Diamond Light Source's eBIC, funded by a £15.6 million Wellcome Trust, MRC and BBSRC grant.

Other jurisdictions

The commercial cryo-EM map is genuinely international, which matters if you plan to serve cross-border clients. NovAliX runs a cryo-EM CRO in Strasbourg, France; Proteros serves EU pharma from Germany; Charles River is adding GMP cryo-EM services in Germany; and Shuimu Biosciences operates eight Krios G4 microscopes for global CRO work from China. If your target accounts are multinational, your plan should address data residency, IP protection and cross-border sample logistics rather than assuming a single-jurisdiction footprint.

Cryo-EM Terms for Founders

Investors will not expect you to be a microscopist, but they will expect your plan to use the vocabulary correctly. These are the terms that recur in client conversations and diligence.

• Single-particle analysis (SPA): the dominant cryo-EM method, reconstructing a 3D structure by averaging thousands of individual particle images. It is the workhorse behind most drug-discovery projects.
• Cryo-ET (electron tomography): imaging a sample from multiple tilt angles to reconstruct cellular context; a higher-value, lower-volume service line.
• Titan Krios: Thermo Fisher's 300 kV flagship, the reference instrument for high-resolution structure determination.
• Glacios / Talos Arctica / Tundra: lower-voltage screening and entry instruments used to triage samples before Krios time.
• Direct electron detector (Gatan K3, Falcon 4): the camera that made the "resolution revolution" possible; a major capital line in its own right.
• Vitrobot: the plunge-freezing device that vitrifies samples on grids — the step where many projects succeed or fail.
• RELION & cryoSPARC: the two dominant software packages for processing cryo-EM data into structures.
• EPU: Thermo Fisher's automated data-collection software that runs long, unattended imaging sessions.
• Sample-to-structure: the end-to-end service promise — client ships a sample, receives a solved structure — and the phrase clients use to compare providers.

Sample Business Plan Preview

Here's an extract from a cryo-EM service business plan written by our team, so you can see the level of specificity investors expect:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a cryo-EM service business:

• Executive Summary — Your facility model, target clients and funding ask, written to hook an equipment lender or investor in 60 seconds
• Company Overview — Legal structure (including any equipment-owning entity), ownership, location rationale and founding story
• Industry Analysis — Cryo-EM market size, the services segment, and the drug-discovery demand drivers behind it
• Customer Analysis — Biotech, pharma and academic segments, buying triggers and the repeat-work profile of medicinal-chemistry accounts
• Competitor Analysis — Positioning against academic cores and named CROs on turnaround, confidentiality and compliance
• Service & Operations Plan — Sample-to-structure workflow, instrument plan, quality system and the utilisation ramp
• Marketing Plan — How you reach structural-biology and discovery buyers through referrals, conferences and technical content
• Management Team — Founder credentials, technical bench strength and the advisory board diligence expects

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis and — critically for this niche — an instrument-utilisation ramp that ties day-rate and project revenue to debt service. You can also start from our free business plan template, explore a done-with-you build via market research and content, or compare adjacent deep-tech niches such as a biotechnology business plan template.

Frequently Asked Questions